TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of TransMedics Group, Inc. (NASDAQ:TMDX – Get Rating) have received a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $53.29.

Several analysts recently weighed in on TMDX shares. Cowen lifted their price objective on TransMedics Group from $60.00 to $70.00 in a report on Friday, December 16th. Morgan Stanley lifted their price objective on TransMedics Group from $54.00 to $63.00 and gave the company an “equal weight” rating in a report on Friday, January 6th. Finally, Canaccord Genuity Group lifted their price objective on TransMedics Group from $58.00 to $63.00 and gave the company a “buy” rating in a report on Friday, November 4th.

Insiders Place Their Bets

In other TransMedics Group news, VP John F. Carey sold 3,000 shares of the business’s stock in a transaction dated Tuesday, November 1st. The shares were sold at an average price of $49.03, for a total value of $147,090.00. Following the completion of the transaction, the vice president now directly owns 771 shares in the company, valued at $37,802.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other TransMedics Group news, VP John F. Carey sold 3,000 shares of the business’s stock in a transaction dated Tuesday, November 1st. The shares were sold at an average price of $49.03, for a total value of $147,090.00. Following the completion of the transaction, the vice president now directly owns 771 shares in the company, valued at $37,802.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Tamer I. Khayal sold 5,558 shares of the business’s stock in a transaction dated Friday, January 20th. The stock was sold at an average price of $65.21, for a total transaction of $362,437.18. Following the completion of the transaction, the insider now owns 1,300 shares of the company’s stock, valued at $84,773. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 129,563 shares of company stock worth $7,764,321. 8.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On TransMedics Group

A number of large investors have recently modified their holdings of TMDX. MinichMacGregor Wealth Management LLC purchased a new stake in shares of TransMedics Group during the fourth quarter worth about $42,000. MCF Advisors LLC purchased a new stake in shares of TransMedics Group during the third quarter worth about $43,000. Royal Bank of Canada grew its stake in shares of TransMedics Group by 643.0% during the third quarter. Royal Bank of Canada now owns 1,122 shares of the company’s stock worth $46,000 after acquiring an additional 971 shares during the last quarter. Prospera Financial Services Inc purchased a new stake in shares of TransMedics Group during the second quarter worth about $69,000. Finally, Tower Research Capital LLC TRC grew its stake in shares of TransMedics Group by 125.4% during the third quarter. Tower Research Capital LLC TRC now owns 2,603 shares of the company’s stock worth $109,000 after acquiring an additional 1,448 shares during the last quarter. Hedge funds and other institutional investors own 88.58% of the company’s stock.

TransMedics Group Trading Up 2.7 %

TMDX opened at $66.06 on Tuesday. The stock has a market cap of $2.11 billion, a price-to-earnings ratio of -44.04 and a beta of 1.57. The stock’s 50 day moving average price is $59.39 and its 200-day moving average price is $50.13. TransMedics Group has a one year low of $10.00 and a one year high of $67.00. The company has a debt-to-equity ratio of 0.31, a quick ratio of 11.21 and a current ratio of 12.11.

TransMedics Group (NASDAQ:TMDX – Get Rating) last released its quarterly earnings data on Thursday, November 3rd. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.15. The company had revenue of $25.68 million for the quarter, compared to the consensus estimate of $18.96 million. TransMedics Group had a negative return on equity of 46.03% and a negative net margin of 58.78%. On average, equities analysts forecast that TransMedics Group will post -1.3 EPS for the current year.

About TransMedics Group

(Get Rating)

TransMedics Group, Inc operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.